this post was submitted on 04 Jan 2024
21 points (100.0% liked)

World In Progress

195 readers
1 users here now

WIP (World In Progress) intends to show all the positive progress going on in the world. It includes progress in technology, medicin, climate etc and not personal uplifting news.

founded 1 year ago
MODERATORS
 

Donanemab and Lecanemab work by clearing the amyloid protein that builds up in the brains of people with Alzheimer’s. Trials suggest they can slow cognitive decline, but not halt the disease. The drugs – set for UK approval in 2024 – mark a turning point in treating a disease that is expected to affect 1.7m Britons by 2040.

“We’re now on the cusp of a first generation of treatments for Alzheimer’s, something that many thought impossible only a decade ago,” said Dr Susan Kohlhaas, executive director of research at Alzheimer’s Research UK. “People should be really encouraged by this news.”

Source headline 4

you are viewing a single comment's thread
view the rest of the comments
[–] themurphy 2 points 1 year ago

It's gonna be exciting to follow in the coming years how much of an impact these can have, and hopefully they are just the beginning.